PUMA BIOTECHNOLOGY, INC. Income Tax Expense
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Income Tax Expense of $4.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-02-26
- PUMA BIOTECHNOLOGY, INC. income tax expense (benefit) for the quarter ending 2024-12-31 was -$7.07M, a 1418.47% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. income tax expense (benefit) for the quarter ending 2024-09-30 was $291.00K, a 36.62% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. income tax expense (benefit) for the quarter ending 2024-06-30 was $378.00K, a 102.14% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. income tax expense (benefit) for the quarter ending 2024-03-31 was $220.00K, a 49.66% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. income tax expense (benefit) for fiscal 2025 was $4.67M.
- PUMA BIOTECHNOLOGY, INC. income tax expense (benefit) for fiscal 2024 was -$6.18M, a 670.45% decline from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. income tax expense (benefit) for fiscal 2023 was $1.08M, a 138.02% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. income tax expense (benefit) for fiscal 2022 was $455.00K, a 40.43% increase from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.67M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | -$7.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.78M derived: sum of 2 quarters · filed 2026-02-26 | -$6.40M derived: sum of 3 quarters · filed 2026-02-26 | -$6.18M 10-K · filed 2026-02-26 |
| 2024-09-30 | $291.00K 10-Q · filed 2024-11-07 | $669.00K derived: sum of 2 quarters · filed 2024-11-07 | $889.00K 10-Q · filed 2024-11-07 | $1.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $378.00K 10-Q · filed 2024-08-01 | $598.00K 10-Q · filed 2024-08-01 | $1.13M derived: sum of 3 quarters · filed 2026-02-26 | $1.35M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $220.00K 10-Q · filed 2024-05-02 | $756.00K derived: sum of 2 quarters · filed 2026-02-26 | $969.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $536.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $749.00K derived: sum of 2 quarters · filed 2026-02-26 | $936.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.08M 10-K · filed 2026-02-26 |
| 2023-09-30 | $213.00K 10-Q · filed 2024-11-07 | $400.00K derived: sum of 2 quarters · filed 2024-11-07 | $547.00K 10-Q · filed 2024-11-07 | $841.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $187.00K 10-Q · filed 2024-08-01 | $334.00K 10-Q · filed 2024-08-01 | $628.00K derived: sum of 3 quarters · filed 2025-02-27 | $695.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $147.00K 10-Q · filed 2024-05-02 | $441.00K derived: sum of 2 quarters · filed 2025-02-27 | $508.00K derived: sum of 3 quarters · filed 2025-02-27 | $565.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $361.00K derived: sum of 2 quarters · filed 2025-02-27 | $418.00K derived: sum of 3 quarters · filed 2025-02-27 | $455.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $67.00K 10-Q · filed 2023-11-02 | $124.00K derived: sum of 2 quarters · filed 2023-11-02 | $161.00K 10-Q · filed 2023-11-02 | $373.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $57.00K 10-Q · filed 2023-08-03 | $94.00K 10-Q · filed 2023-08-03 | $306.00K derived: sum of 3 quarters · filed 2024-02-29 | $343.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $37.00K 10-Q · filed 2023-05-04 | $249.00K derived: sum of 2 quarters · filed 2024-02-29 | $286.00K derived: sum of 3 quarters · filed 2024-02-29 | $324.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $212.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $249.00K derived: sum of 2 quarters · filed 2024-02-29 | $287.00K derived: sum of 3 quarters · filed 2024-02-29 | $324.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $37.00K 10-Q · filed 2022-11-03 | $75.00K derived: sum of 2 quarters · filed 2022-11-03 | $112.00K 10-Q · filed 2022-11-03 | $320.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $38.00K 10-Q · filed 2022-08-04 | $75.00K 10-Q · filed 2022-08-04 | $283.00K derived: sum of 3 quarters · filed 2023-03-02 | $283.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $38.00K 10-Q · filed 2022-05-05 | $245.00K derived: sum of 2 quarters · filed 2023-03-02 | $245.00K derived: sum of 3 quarters · filed 2023-03-02 | |
| 2020-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $207.00K derived: sum of 2 quarters · filed 2023-03-02 | $207.00K 10-K · filed 2023-03-02 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | $53.00K 10-K · filed 2022-03-03 | |||
| 2018-12-31 | $17.00K 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-28 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-09 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |